Rain oncology stock.

Cardiff Oncology stock price target cut to $14 from $25 at Maxim Group. Jan. 24, 2022 at 7:47 a.m. ET by Tomi Kilgore. Cardiff Oncology stock price target raised to $25 from $20 at Maxim Group.The number of outstanding shares of the company’s common stock is not affected by the name change. The company’s ticker symbol “RAIN” will remain the same. About Rain Oncology.1,000+ best royalty free rain videos & rainfall stock video clips & footage. Download high-quality HD & 4K rain videos on desktop or mobile for your next project. Royalty-free videos. waterfall water river. 4K 00:20. rain water window wet. HD 00:33. rain thunder water. SD 00:36. rainy rain night. HD 01:01. storm ocean sky rain. HD 00:40. rain ...Rain Oncology last announced its earnings data on November 9th, 2023. The reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.08. Rain Oncology has generated ($2.06) earnings per share over the last year (($2.06) diluted earnings per share).

Oct 16, 2023 · Oct 16, 2023. NEWARK, Calif., October 16, 2023 – Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right (“CVR”) representing the right to receive 80% of the net ... View the latest Oncology Pharma Inc. (ONPH) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Apr 18, 2023 · Rain Oncology Inc (RAIN) stock is trading at $7.36 as of 1:33 PM on Tuesday, Apr 18, a loss of -$0.08, or -1.08% from the previous closing price of $7.44. The stock has traded between $7.20 and $7.45 so far today. Volume today is less active than usual. Jun 21, 2023 · NEW YORK, June 21, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Rain Oncology Inc.:. On or around April 22, 2021, Rain conducted its initial public offering ("IPO"), selling more than 7.35 million shares priced at $17.00.

Purpose: This study evaluated the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of milademetan, a small-molecule murine double minute-2 (MDM2) inhibitor, in patients with advanced cancers. Patients and methods: In this first-in-human phase I study, patients with advanced solid tumors or lymphomas …NEWARK, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology... – Quarter-end cash position of $123.2 million provides ample cash runway into first half of 2024 – – Phase 3 MANTRA topline data expected earlier than... May 5, 2023 · Insiders who bought Rain Oncology Inc. (NASDAQ:RAIN) stock in the last 12 months were richly rewarded last week. The company's market value increased by US$54m as a result of the stock's 21% gain ... Track Rain Therapeutics Inc (RAIN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsWebNEWARK, Calif., October 16, 2023 – Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC …

1.0900. +0.0200. +1.87%. Rain Therapeutics Inc. (NASDAQ:RAIN) Q4 2022 Earnings Call Transcript March 9, 2023 Operator: Greetings and welcome to the Rain Oncology Fourth Quarter and Full Year 2022 ...Web

May 22, 2023 · Rain Oncology Inc (NASDAQ: RAIN) announced topline Phase 3 MANTRA data of milademetan in patients with dedifferentiated (DD) liposarcoma (LPS). The study did not meet its primary endpoint of ...

Most recently, on Monday, November 21st, Franklin M. Berger bought 45,000 shares of Rain Oncology stock. The stock was acquired at an average cost of $7.80 per share, with a total value of $351,000.00. Following the completion of the transaction, the director now directly owns 928,207 shares of the company's stock, valued at $7,240,014.60.ETFs & Funds. A high-level overview of Rain Oncology Inc. (RAIN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading …This one-day volume growth resulted in a record-breaking increase of 210%, as compared to the 65-Day Volume Moving Average. RAIN's total volume now sits at 584.3K. The -1.89% price change was insignificant, leaving RAIN's price at $1.04. This volume move could indicate a change in trend, and may be a buy signal for investors. A.I.dvisor found 35 …Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer.PFS (Primary): Approximately 105 events by blinded central review to trigger primary analysis. OS, ORR, DCR, DOR. Safety. TP53. Overview. MDM2 gene CN of ≥8. Patients enrolled based on local NGS for CN, centrally confirmed by Rain's diagnostic partner, Tempus. Evaluable tumor types included: lung, breast, biliary, pancreatic and other select ... Dec 29, 2022 · The number of outstanding shares of the company’s common stock is not affected by the name change. The company’s ticker symbol “RAIN” will remain the same. About Rain Oncology.

Let's dive into the best cancer stocks to consider. 1. Pfizer. While Pfizer Inc. (NYSE: PFE) made recent news with its COVID-19 vaccination, it has long been one of the top cancer research stocks ...Analyst Recommendations on Rain Oncology Inc. Citigroup Trims Rain Oncology's Price Target to $1 From 1.50, Keeps Neutral Rating. Sep. 18. MT. Mizuho Downgrades Rain Oncology to Neutral From Buy, Adjusts Price Target to $1 From $17. Jun. 05. MT. EF Hutton Cuts Rain Oncology's Price Target to $2 From $5, Maintains Hold Rating.Details · Stock Symbol NASDAQ:RAIN · Company Type For Profit.Nov 9, 2023 · NEWARK, Calif., October 16, 2023 – Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right (“CVR”) representing ... At Olema Oncology, we leverage our deep understanding of endocrine-driven cancers, nuclear receptors and mechanisms of acquired resistance with the goal of transforming the standard of care for women living with cancer by focusing on developing more convenient and effective therapies. Join us as we aim to design therapies for improving lives.Analyst Recommendations on Rain Oncology Inc. Citigroup Trims Rain Oncology's Price Target to $1 From 1.50, Keeps Neutral Rating. Sep. 18. MT. Mizuho Downgrades Rain Oncology to Neutral From Buy, Adjusts Price Target to $1 From $17. Jun. 05. MT. EF Hutton Cuts Rain Oncology's Price Target to $2 From $5, Maintains Hold Rating.

Rain Therapeutics. NEWARK, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”) (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology ...Complete Rain Oncology Inc. stock information by Barron's. View real-time RAIN stock price and news, along with industry-best analysis.

Rain Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Progress ... Non-cash stock-based compensation expenses included in R&D expenses were approximately $1.1 million in the three months ended March 31, 2023, as compared to $0.9 million in the same period in 2022. General and administrative (G&A) …WebMost recently, on Monday, November 21st, Franklin M. Berger bought 45,000 shares of Rain Oncology stock. The stock was acquired at an average cost of $7.80 per share, with a total value of $351,000.00. Following the completion of the transaction, the director now directly owns 928,207 shares of the company's stock, valued at …WebThe company's lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p53. The company was formerly known as Rain Therapeutics Inc. and changed its name to Rain Oncology Inc. in December 2022. Rain Oncology Inc. was incorporated in 2017 and is headquartered in Newark, California.Get the latest Rain Oncology Inc. (RAIN) stock news and headlines to help you in your trading and investing decisions. Rain Oncology, Inc. is a clinical-stage precision oncology company, which focuses on developing and implement the precision oncology therapies for patients suffering from cancer. The company was founded by Avanish Vellanki and Robert Doebele in April 2017 and is headquartered in Newark, CA. May 22, 2023 · Shares of Rain Oncology ( RAIN 0.96%) were down 87% Monday afternoon after the precision oncology company released top-line results for its lead therapy, milademetan, to treat dedifferentiated ... NEWARK, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics with its lead product candidate ...About Rain Oncology Inc. Rain Oncology Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology.Rain Oncology (NASDAQ: RAIN) stock is taking a massive beating on Monday after the company revealed its latest clinical trial data. The bad news for investors in RAIN stock is the company’s ...Web

Of course Rain Oncology may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

Rain Oncology, Inc. (NASDAQ: RAIN) Class Period: July 20, 2021 - May 19, 2023. ... In response to the announcement, Rain’s stock price substantially dropped from $9.93 per share to $1.22 per share, eliminating approximately $316 million in market capitalization in one day.

We see a spike in Rain Oncology’s stock price after the offer though it is still $0.20 below the $1.25 offer price which does leave out some premium for M&A arbitrageurs. The intriguing aspect of this development is the involvement of Tang Capital Partners, which had previously disclosed a substantial 14.1% stake in Rain Oncology.WebView the latest Oncology Pharma Inc. (ONPH) stock price, news, historical charts, analyst ratings and financial information from WSJ.31 Jan 2023 ... Roth Capital Partners renewed coverage of Rain Oncology (Rain Oncology Stock Quote, Charts, News, Analysts, Financials NASDAQ:RAIN) on ...Rain Therapeutics (RAIN) LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Rain Therapeutics today and set a price target of $17.00 . The company’s shares closed last Thursday at $9.28.WebIn the previous week, Rain Oncology had 18 more articles in the media than Celularity. MarketBeat recorded 21 mentions for Rain Oncology and 3 mentions for Celularity. Rain Oncology's average media sentiment score of 0.63 beat Celularity's score of -0.07 indicating that Celularity is being referred to more favorably in the media.WebThe oncology industry is expected to grow considerably in 2022, driven by the rising occurrence of cancer in the U.S. population. Furthermore, increasing investments by biopharmaceutical companies and the government should fuel the industry's growth. Given the industry's bright growth prospects, Wall Street analysts expect the stocks of …Rain Oncology ( NASDAQ: RAIN) has received an acquisition proposal from Concentra Biosciences, an affiliate of Tang Capital Partners, for $1.25/share in cash. The clinical-stage micro-cap cancer ...May 5, 2023 · Insiders who bought Rain Oncology Inc. (NASDAQ:RAIN) stock in the last 12 months were richly rewarded last week. The company's market value increased by US$54m as a result of the stock's 21% gain ... JaysonPhotography. Rain Oncology (NASDAQ:RAIN) continued to fall in the pre-market Tuesday after multiple analysts downgraded the company on its decision to halt studies for its lead asset ...

Analyst Recommendations on Rain Oncology Inc. Citigroup Trims Rain Oncology's Price Target to $1 From 1.50, Keeps Neutral Rating. Sep. 18. MT. Mizuho Downgrades Rain Oncology to Neutral From Buy, Adjusts Price Target to $1 From $17. Jun. 05. MT. EF Hutton Cuts Rain Oncology's Price Target to $2 From $5, Maintains Hold Rating.AI Stock 12 Months Forecast. Based on 10 Wall Street analysts offering 12 month price targets for C3ai in the last 3 months. The average price target is $25.00 with a high forecast of $42.00 and a low forecast of $14.00. The average price target represents a -9.42% change from the last price of $27.60.Nov 24, 2023 · Company Summary. Rain Oncology Inc. is a late-stage precision oncology company developing therapies which target oncogenic drivers to genetically select patients. The company's lead product ... Coming off stock drops following safety concerns over its recently approved eye injection Syfovre--which turned out to be related to the needle used to deliver the medicine, ... Rain Oncology is laying off 65% of its staff, including its chief medical officer. This news came one week after the company's lead candidate, ...Instagram:https://instagram. afeelaswayfair stocktwitsnextra energy stockbest forex prop firm 2023 Nov 4, 2022 · Nov 04, 2022. NEWARK, Calif., November 4, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the pricing of a registered offering of 6,861,080 shares of common stock and 1,715,250 shares of non-voting common stock. The shares are being sold at an offering price of $5.83 per ... Stock Price Forecast The 4 analysts offering 12-month price forecasts for Rain Oncology Inc have a median target of 1.38, with a high estimate of 2.00 and a low estimate of 1.00.Web ouster lidar stockncr ltd 31 May 2023 ... Rain plans to continue evaluating the Phase 3 MANTRA data and present those findings at a medical conference later in the year. The company also ...Rain Oncology Inc. Watch list NEW Set a price target alert After Hours Last Updated: Dec 1, 2023 7:58 p.m. EST Delayed quote $ 1.1100 0.00 0.00% After Hours Volume: 1.31K Advanced Charting... soundhound stock prediction Clovis Oncology (NASDAQ:CLVS) issued its quarterly earnings data on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.08. The biopharmaceutical company had revenue of $37.92 million for the quarter, compared to …NEWARK, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”) (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that it will …WebRain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update. Find the latest Rain Oncology Inc. (RAIN) stock quote, history, news and other vital...